Cytokinetics Inc Dossier
Qualitative Analysis
Business overview
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The company's primary commercial asset is MYQORZO (aficamten), an allosteric and reversible cardiac myosin inhibitor approved in the United States, China, and the European Union for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also advancing aficamten for non-obstructive HCM, alongside a broader pipeline of cardiac muscle modulators including omecamtiv mecarbil and ulacamten.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Executing the commercial launch of MYQORZO (aficamten) in the United States, Germany, and other European countries following regulatory approvals.
Expected impact: Establishes Cytokinetics as a commercial-stage biopharmaceutical company and drives initial product sales.
A company-wide unifying campaign and strategic framework designed to strengthen organizational readiness, scale global commercial capabilities, and transition Cytokinetics into a leading muscle-focused specialty biopharmaceutical company.
Expected impact: Aims to build a sustainable, multi-product global biopharma leader with expanded pipeline programs and commercial infrastructure.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Sanofi holds exclusive rights to develop and commercialize MYQORZO (aficamten) in Greater China, leveraging its extensive local cardiovascular commercial expertise.
Terms: Cytokinetics received a $15 million regulatory milestone payment triggered by approvals in late 2025, and remains eligible to receive up to $142.5 million in additional development and commercial milestones, plus royalties in the low-to-high teens on net sales.
Provides diversified access to capital to support the commercial launch of aficamten and co-fund the development of adjacent pipeline candidates like CK-586 and omecamtiv mecarbil.
Terms: Total collaboration value of up to $575 million, including upfront capital, equity purchases, and R&D co-funding (such as up to $75 million for a Phase 2b study of CK-586 in 2026 with options for up to $425 million more).